Company profile for Prota Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Prota Therapeutics is an Australian, proprietary limited, privately-held biotech company established in 2016 to develop and commercialize novel oral immunotherapy treatments. Prota holds an exclusive license to the proprietary food immunotherapy technology, developed at the MCRI. Series A funding of AUD $15m was secured from OneVentures, a leading Australian venture capital investment firm (OneVentures’ Healthcare Fund III) ...
Prota Therapeutics is an Australian, proprietary limited, privately-held biotech company established in 2016 to develop and commercialize novel oral immunotherapy treatments. Prota holds an exclusive license to the proprietary food immunotherapy technology, developed at the MCRI. Series A funding of AUD $15m was secured from OneVentures, a leading Australian venture capital investment firm (OneVentures’ Healthcare Fund III) – including $5M from the Australian Commonwealth Government Biomedical Translation Fund – as well as private investment.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Australia
Address
Address
c/o FB Rice Reception Level 33, 477 Collins Street Melbourne Vic 3000
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2025-09-16/prota-therapeutics-announces-prt120-follow-on-study-awarded-eaaci-prize-for-long-term-post-treatment

PHARMAWEB
16 Sep 2025

https://www.prnewswire.com/news-releases/prota-therapeutics-announces-publication-in-allergy-of-long-term-peanut-allergy-study-confirming-clinical-remission-as-the-optimal-treatment-outcome-302222276.html

PR NEWSWIRE
14 Aug 2024

https://www.prnewswire.com/news-releases/prota-therapeutics-ceo-mimi-tang-honoured-at-biomelbourne-networks-women-in-leadership-awards-2024-302129874.html

PR NEWSWIRE
29 Apr 2024

https://www.accesswire.com/viewarticle.aspx?id=825158&lang=en

ACCESSWIRE
16 Jan 2024

https://www.prnewswire.com/news-releases/prota-therapeutics-achieves-51-percent-peanut-allergy-remission-rate-first-company-to-validate-significant-quality-of-life-improvements-compared-with-standard-care-301547484.html

PRNEWSWIRE
16 May 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty